

**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 59705

**Manuscript Type:** CASE REPORT

**Metastatic thymic-enteric adenocarcinoma type responding to chemoradiation plus anti-angiogenic therapy: A case report**

Li M *et al.* A case report of metastatic thymic-enteric adenocarcinoma type

Man Li, Xiao-Yu Pu, Li-Hua Dong, Peng-Yu Chang

### Abstract

#### BACKGROUND

Thymic-enteric adenocarcinoma with positive expression of CDX2 and CK20 is rare in adults, with only 16 reported cases. However, standard treatment options for this type of thymic adenocarcinoma has not yet been established. Therefore, we report a case of stage IV thymic-enteric adenocarcinoma treated with radiotherapy, chemotherapy, and

### Match Overview

Match Number	Source	Words	Similarity
1	Internet www.vjgnet.com	46 words crawled on 08-Aug-2020	4%
2	Internet www.mdpi.com	28 words crawled on 23-Aug-2020	2%
3	Internet journals.lww.com	10 words crawled on 06-Jun-2020	1%
4	Internet www.coursehero.com	8 words crawled on 25-Jun-2020	1%
5	Crossref Rectal Cancer, 2010.	6 words	<1%

Metastatic thymic-enteric adenocarcinoma type responding to ch



ALL

IMAGES

VIDEOS

41,700 Results

Any time ▾

## Systemic therapy for cervical carcinoma – current status

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953957>

There are currently only four **case** reports on the use of pembrolizumab and nivolumab in the **metastatic** setting, including chemo-refractory and PD-L1-negative tumors (73-75). A rapid **response** or **response** following transit increase of lesions was reported.

**Cited by:** 6

**Author:** Krystyna Serkies, Jacek Jassem

**Publish Year:** 2018

## Clinicopathologic characteristics and survival of patients ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096388>

INTRODUCTION. **Metastatic** brain lesions are uncommon in gynecologic malignancies; they occur in 0.3–0.9% of uterine corpus cancers [1–3], 0.3–11.6% of ovarian cancers [4–9], and 0.4–2.3% of cervical cancers [10–13]. Although rare, such lesions have become a focus of interest as advances in multimodality treatments are prolonging survival among gynecologic cancer patients, thereby ...

**Cited by:** 12

**Author:** Laura M. Divine, Nora T. Kizer, Andrea R...

**Publish Year:** 2016

## Systemic therapy for recurrent or metastatic salivary ...

<https://cancersheadneck.biomedcentral.com/articles/10.1186/s41199-016-0011-z>

Sep 01, 2016 · Salivary gland carcinomas are notoriously resistant to **therapy** and no standard of care exists. Due to the rarity of these malignancies, various histologies, and wide ranging clinical behavior it has been difficult to standardize systemic **therapy**. We have reviewed clinical prospective studies in the last 15 years with salivary gland malignancies involving cytotoxic ...

**Cited by:** 7

**Author:** Ashish V. Chintakuntlawar, Scott H. Oku...

**Publish Year:** 2016

42,900 Results Any time

### Systemic therapy for cervical carcinoma – current status

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953957>

Aug 30, 2017 · A rapid response or response following transit increase of lesions was reported. Of those, there was a case of neuroendocrine cervical carcinoma with near-complete systemic resolution of disease, ongoing at 10+ months after nivolumab, sandostatin and stereotactic body radiation therapy (SBRT; 20 Gy/4 fractions) including abdominal mass . The ...

Cited by: 6 Author: Krystyna Serkies, Jacek Jassem  
Publish Year: 2018

### Clinicopathologic characteristics and survival of patients ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096388>

INTRODUCTION. Metastatic brain lesions are uncommon in gynecologic malignancies; they occur in 0.3–0.9% of uterine corpus cancers [1–3], 0.3–11.6% of ovarian cancers [4–9], and 0.4–2.3% of cervical cancers [10–13]. Although rare, such lesions have become a focus of interest as advances in multimodality treatments are prolonging survival among gynecologic cancer patients, thereby ...

Cited by: 12 Author: Laura M. Divine, Nora T. Kizer, Andrea R. Ha...  
Publish Year: 2016

#### PEOPLE ALSO ASK

- Can chemotherapy treat salivary cancer? ▾
- Is salivary gland carcinoma chemotherapy effective? ▾
- Is immunotherapy used to treat cancer? ▾
- What is metastatic salivary gland cancer? ▾

Feedback

### Systemic therapy for recurrent or metastatic salivary ...

<https://cancersheadneck.biomedcentral.com/articles/...>

Sep 01, 2016 · Salivary gland carcinomas are notoriously resistant to therapy and no standard of care exists. Due to the rarity of these malignancies, various histologies, and wide ranging clinical behavior it has been difficult to standardize systemic therapy. We have reviewed clinical prospective studies in the last 15 years with salivary gland malignancies involving cytotoxic chemotherapy and biologic ...

Cited by: 8 Author: Ashish V. Chintakuntlawar, Scott H. Okuno, ...  
Publish Year: 2016

### Chemotherapy for Advanced Thymic Carcinoma: Clinical ...

<https://www.researchgate.net/publication/11333380...>

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report Article Full-text available

### Clinical response in patients with ovarian cancer treated ...

<https://ecancer.org/en/journal/article/723...>

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy. Herman Andrés Perroud 1,2,3, O Graciela Scharovsky 1,2,4, Viviana Rosa Rozados 1 and Carlos María Alasino 3,5. 1 Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario 2000, Argentina. 2 National Scientific and Technical ...

Cited by: 3 Author: Herman Andrés Perroud, O Graciela Scharo...  
Publish Year: 2017

### Strategic plans to promote head and neck cancer ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2064008>

Clinical trials of combined modality therapy or radiation dose intensification have led to incremental improvement in head and neck cancer outcomes, resulting in improved local control, organ preservation, and/or survival. Radiation therapy (RT) remains a critical component of this success.

### Combining Bevacizumab with Radiation or Chemoradiation for ...

[europepmc.org/articles/PMC4069862](http://europepmc.org/articles/PMC4069862)

Anti-angiogenic therapy may result in an initial response followed by relapse in some patients or in lack of initial benefit for other patients. This suggests two modes of resistance: evasive resistance, where tumors adapt during treatment, and intrinsic resistance where counteracting mechanisms are ...

### Progress on Antiangiogenic Therapy for Patients with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850510>

The anti-angiogenic therapy failures described above are thought to be due to the development of resistance to anti-angiogenic therapy. Resistance to anti-angiogenic therapy has been broadly classified as either adaptive or intrinsic . Animal models of malignant glioma and of other malignant tumors have shown that tumors adapt to treatment with ...

### Angiogenesis inhibitors in the treatment of prostate cancer

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922886>

The application of anti-angiogenic therapy to prostate cancer is reviewed in this article, with attention to efficacy and toxicity results from several classes of anti-angiogenic agents. Ultimately, the fate of anti-angiogenic agents in prostate cancer rests on the eagerly anticipated results of ...

### Immunotherapy for Cancer - National Cancer Institute

<https://www.cancer.gov/about-cancer/treatment/types/immunotherapy>

Sep 24, 2019 · Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system. Immunotherapy is a type of biological therapy. Biological therapy is a type of treatment that uses substances made from living organisms to ...



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

43,700 Results

Any time ▾

## Systemic therapy for cervical carcinoma – current status

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953957>

Aug 30, 2017 · A rapid **response** or **response** following transit increase of lesions was reported. Of those, there was a **case** of neuroendocrine cervical carcinoma with near-complete systemic resolution of disease, ongoing at 10+ months after nivolumab, sandostatin and stereotactic body radiation **therapy** (SBRT; 20 Gy/4 fractions) including abdominal mass . The ...

**Cited by:** 6

**Author:** Krystyna Serkies, Jacek Jassem

**Publish Year:** 2018

## Clinicopathologic characteristics and survival of patients ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096388>

INTRODUCTION. **Metastatic** brain lesions are uncommon in gynecologic malignancies; they occur in 0.3–0.9% of uterine corpus cancers [1–3], 0.3–11.6% of ovarian cancers [4–9], and 0.4–2.3% of cervical cancers [10–13]. Although rare, such lesions have become a focus of interest as advances in multimodality treatments are prolonging survival among gynecologic cancer patients, thereby ...

**Cited by:** 12

**Author:** Laura M. Divine, Nora T. Kizer, Andrea R. Ha...

**Publish Year:** 2016

### PEOPLE ALSO ASK

Is salivary gland carcinoma chemotherapy effective? ▾

Can chemotherapy treat salivary cancer? ▾

Are salivary gland carcinomas systemic? ▾

What is metastatic salivary gland cancer? ▾